Jump to content

Isopropylphenidate: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Changes the modulecular 2D skeletal rendering to the correct PUBCHEM one
No edit summary
Line 27: Line 27:
}}
}}


'''Isopropylphenidate''' (also known as '''IPH''' and '''IPPD''') is a [[piperidine]] based [[stimulant]] drug, closely related to [[methylphenidate]], but with the methyl [[ester]] replaced by an [[isopropyl]] ester. It has similar effects to methylphenidate but with a longer duration of action,<ref>{{cite journal | vauthors = Markowitz JS, Zhu HJ, Patrick KS | title = Isopropylphenidate: an ester homolog of methylphenidate with sustained and selective dopaminergic activity and reduced drug interaction liability | journal = Journal of Child and Adolescent Psychopharmacology | volume = 23 | issue = 10 | pages = 648–54 | date = December 2013 | pmid = 24261661 | doi = 10.1089/cap.2013.0074 | url = https://deepblue.lib.umich.edu/bitstream/2027.42/140321/1/cap.2013.0074.pdf }}</ref><ref>{{cite patent | url=http://www.google.com/patents/US20120245201 | country = US | number = 20120245201 | status = application | title = Isopropylphenidate for Treatment of Attention-Deficit/Hyperactivity Disorder and Fatigue-Related Disorders and Conditions | pdate = 27 September 2012 | access-date=15 August 2014 | inventor = Markowitz JS, Patrick KS, Zhu H }}</ref> and was banned in the UK as a [[Temporary Class Drug]] from April 2015 following its unapproved sale as a [[designer drug]].<ref>{{cite web | url = https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/420983/TCDO_methylphenidate_NPS.pdf | title = Methylphenidate-based NPS: A review of the evidence of use and harm. | work = Advisory Council on the Misuse of Drugs | date = 31 March 2015 }}</ref>
'''Isopropylphenidate''' (also known as '''IPH''' and '''IPPD''') is a [[piperidine]] based [[stimulant]] drug, closely related to [[methylphenidate]], but with the methyl [[ester]] replaced by an [[isopropyl]] ester. It has similar effects to methylphenidate but with a longer duration of action,<ref>{{cite journal | vauthors = Markowitz JS, Zhu HJ, Patrick KS | title = Isopropylphenidate: an ester homolog of methylphenidate with sustained and selective dopaminergic activity and reduced drug interaction liability | journal = Journal of Child and Adolescent Psychopharmacology | volume = 23 | issue = 10 | pages = 648–54 | date = December 2013 | pmid = 24261661 | doi = 10.1089/cap.2013.0074 | url = https://deepblue.lib.umich.edu/bitstream/2027.42/140321/1/cap.2013.0074.pdf }}</ref><ref name="US">{{cite patent | url=http://www.google.com/patents/US20120245201 | country = US | number = 20120245201 | status = application | title = Isopropylphenidate for Treatment of Attention-Deficit/Hyperactivity Disorder and Fatigue-Related Disorders and Conditions | pdate = 27 September 2012 | access-date=15 August 2014 | inventor = Markowitz JS, Patrick KS, Zhu H }}</ref> and was banned in the UK as a [[Temporary Class Drug]] from April 2015 following its unapproved sale as a [[designer drug]].<ref>{{cite web | url = https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/420983/TCDO_methylphenidate_NPS.pdf | title = Methylphenidate-based NPS: A review of the evidence of use and harm. | work = Advisory Council on the Misuse of Drugs | date = 31 March 2015 }}</ref>

It has been researched as potential methylphenidate replacement for [[ADHD]] and [[narcolepsy]], because of fewer side effects.<ref name="pharm">{{cite journal|author=Florence Levy|title=Applications of pharmacogenetics in children with attention-deficit/hyperactivity disorder|journal=Pharmgenomics Pers Med|date=July 2014|pages=349–356.}}</ref><ref name="US"/>


== See also ==
== See also ==

Revision as of 19:27, 22 August 2020

Not to be confused with isopropylphenidine.
Isopropylphenidate
Legal status
Legal status
Identifiers
  • propan-2-yl 2-phenyl-2-(piperidin-2-yl)acetate
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC16H23NO2
Molar mass261.365 g·mol−1
3D model (JSmol)
  • C1(=CC=CC=C1)C(C(=O)OC(C)C)C2CCCCN2
  • InChI=1S/C16H23NO2/c1-12(2)19-16(18)15(13-8-4-3-5-9-13)14-10-6-7-11-17-14/h3-5,8-9,12,14-15,17H,6-7,10-11H2,1-2H3
  • Key:AZVPADMEIMLODT-UHFFFAOYSA-N

Isopropylphenidate (also known as IPH and IPPD) is a piperidine based stimulant drug, closely related to methylphenidate, but with the methyl ester replaced by an isopropyl ester. It has similar effects to methylphenidate but with a longer duration of action,[1][2] and was banned in the UK as a Temporary Class Drug from April 2015 following its unapproved sale as a designer drug.[3]

It has been researched as potential methylphenidate replacement for ADHD and narcolepsy, because of fewer side effects.[4][2]

See also

References

  1. ^ Markowitz JS, Zhu HJ, Patrick KS (December 2013). "Isopropylphenidate: an ester homolog of methylphenidate with sustained and selective dopaminergic activity and reduced drug interaction liability" (PDF). Journal of Child and Adolescent Psychopharmacology. 23 (10): 648–54. doi:10.1089/cap.2013.0074. PMID 24261661.
  2. ^ a b US application 20120245201, Markowitz JS, Patrick KS, Zhu H, "Isopropylphenidate for Treatment of Attention-Deficit/Hyperactivity Disorder and Fatigue-Related Disorders and Conditions" 
  3. ^ "Methylphenidate-based NPS: A review of the evidence of use and harm" (PDF). Advisory Council on the Misuse of Drugs. 31 March 2015.
  4. ^ Florence Levy (July 2014). "Applications of pharmacogenetics in children with attention-deficit/hyperactivity disorder". Pharmgenomics Pers Med: 349–356.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Isopropylphenidate&oldid=974395252"